# EDGAR Filing Document

**Accession Number:** 0001620749
**File Stem:** 0001640334-23-000397
**Filing Date:** 2023-3
**Character Count:** 57822
**Document Hash:** 6d831b8ac97403e98cfa1d84e8aa681e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-23-000397.hdr.sgml**: 20230321

**ACCESSION NUMBER**: 0001640334-23-000397

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 36

**CONFORMED PERIOD OF REPORT**: 20230131

**FILED AS OF DATE**: 20230321

**DATE AS OF CHANGE**: 20230321

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Panamera Holdings Corp
- **CENTRAL INDEX KEY:** 0001620749
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
- **IRS NUMBER:** 465707326
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55569
- **FILM NUMBER:** 23748262

**BUSINESS ADDRESS:**
- **STREET 1:** 1218 WEBSTER STREET
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77002
- **BUSINESS PHONE:** 713-289-6200

**MAIL ADDRESS:**
- **STREET 1:** 1218 WEBSTER STREET
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77002

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PANAMERA HEALTHCARE Corp
- **DATE OF NAME CHANGE:** 20140926

?xml version="1.0" encoding="utf-8"?pnht_10q.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

(Mark One)

---

| | |
|:---|:---|
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|  | For the quarterly period ended **<u>January 31, 2023</u>** |
| or | or |
| ☐ | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|  | For the transition period from ______________ to ______________ |
| Commission File Number **<u>000-55569</u>** | Commission File Number **<u>000-55569</u>** |

---

---

| |
|:---|
| **PANAMERA HOLDINGS CORPORATION** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Nevada** | **46-5707326** |
| (State or other jurisdiction of<br>incorporation or organization) | (IRS Employer<br>Identification No.) |
| **1218 Webster Street Houston, Texas** | **77002** |
| (Address of principal <br>executive offices) | (Zip Code) |

---

**<u>(713) 289-6200</u>**

(Registrant's telephone number, including area code)

**<u>Panamera Healthcare Corporation</u>**

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **None** | **None** | **None** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes&nbsp;&nbsp;&nbsp;&nbsp;☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ Yes ☒ NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. 33,210,000 shares of common stock outstanding as of March 17, 2023

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **[PART I - FINANCIAL INFORMATION](#p1)** | **[PART I - FINANCIAL INFORMATION](#p1)** |  |
| [Item 1.](#i1) | [Financial Statements](#i1) | 3 |
| [Item 2.](#i2) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#i2) | 10 |
| [Item 3.](#i3) | [Quantitative and Qualitative Disclosures About Market Risk](#i3) | 15 |
| [Item 4.](#i4) | [Controls and Procedures](#i4) | 15 |
| **[PART II - OTHER INFORMATION](#p2)** | **[PART II - OTHER INFORMATION](#p2)** |  |
| [Item 1.](#p2i1) | [Legal Proceedings](#p2i1) | 17 |
| [Item 1A.](#p2i1a) | [Risk Factors](#p2i1a) | 17 |
| [Item 2.](#p2i2) | [Unregistered Sales of Equity Securities and Use of Proceeds](#p2i2) | 17 |
| [Item 3.](#p2i3) | [Defaults Upon Senior Securities](#p2i3) | 17 |
| [Item 4.](#p2i4) | [Mine Safety Disclosures](#p2i4) | 17 |
| [Item 5.](#p2i5) | [Other Information](#p2i5) | 17 |
| [Item 6.](#exhibit) | [Exhibits](#exhibit) | 18 |
| [SIGNATURES](#sig) | [SIGNATURES](#sig) | 19 |

---

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#TOC)* |

---

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

 **PANAMERA HOLDINGS CORPORATION**

**Balance Sheets**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **January 31,**<br>**2023** | **July 31,**<br>**2022** |
| **Assets** |  |  |
| Current Assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash | $3675 | $3087 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses |  | 55 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 8333 | 8332 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other receivable - related party | - | 1098 |
| Total Current Assets | 12008 | 12572 |
| **Total Assets** | $12008 | $12572 |
| **Liabilities and Stockholders' Deficit** |  |  |
| Current Liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $22395 | $17034 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payroll liabilities - related party | 8100 | 7706 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue and customer deposits |  | 1500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Due to related party | 43946 | 33946 |
| Total Current Liabilities | 74441 | 60186 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities | 74441 | 60186 |
| Stockholders' Deficit |  |  |
| Preferred stock: 50,000,000 authorized; $0.0001 par value, no shares issued and outstanding |  |  |
| Common stock: 550,000,000 authorized; $0.0001 par value, 39,210,000 shares issued | 3921 | 3921 |
| Additional paid in capital | 348903 | 346505 |
| Treasury stock, at cost: 6,000,000 shares and 0 shares at January 31, 2023 and July 31, 2022, respectively | (600) |  |
| Accumulated deficit | (414657) | (398040) |
| Total Stockholders' Deficit | (62433) | (47614) |
| **Total Liabilities and Stockholders' Deficit** | $12008 | $12572 |

---

*The accompanying notes to the unaudited financial statements are an integral part of these statements.*

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#TOC)* |

---

**PANAMERA HOLDINGS CORPORATION**

**Statements of Operations**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the**  | **For the**  | **For the** | **For the** |
|  | **Three Months Ended** | **Three Months Ended** | **Six Months Ended** | **Six Months Ended** |
|  | **January 31,** | **January 31,** | **January 31,** | **January 31,** |
|  | **2023** | **2022** | **2023** | **2022** |
| Revenues - related party | $25000 | $- | $50001 | $- |
| Cost of revenues - related party | 25970 | - | 48864 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit (loss) | (970) | - | 1137 | - |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional fees | $8167 | $5305 | $13219 | $5333 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administration expenses | 2294 | 932 | 2737 | 3344 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 10461 | 6237 | 15956 | 8677 |
| **Net loss from operations** | (11431) | (6237) | (14819) | (8677) |
| **Other Expense** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (965) | (389) | (1798) | (456) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other expense | (965) | (389) | (1798) | (456) |
| **Net loss before taxes** | (12396) | (6626) | (16617) | (9133) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax benefit |  |  |  |  |
| **Net loss** | $(12396) | $(6626) | $(16617) | $(9133) |
| **Basic and diluted loss per common share** | $(0.00) | $(0.00) | $(0.00) | $(0.00) |
| **Weighted average number of common shares outstanding, basic and diluted** | 35492609 | 39210000 | 37361351 | 39210000 |

---

*The accompanying notes to the unaudited financial statements are an integral part of these statements.*

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#TOC)* |

---

**PANAMERA HOLDINGS CORPORATION**

**Statements of Changes in Stockholders' Deficit**

**(Unaudited)**

***For the Three and Six Months Ended January 31, 2023***

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | **Treasury Stock** | **Treasury Stock** | | |
|  | **Shares**  | **Amount**  | **Additional**<br>**Paid in** <br> **Capital**  | **Shares**  | **Amount**  | <br>**Accumulated**<br> **Deficit**  | <br><br> **Total**  |
| **Balance - July 31, 2022** | 39210000 | $3921 | $346505 |  | $— | $(398040) | $(47614) |
| &nbsp;&nbsp;&nbsp;&nbsp;Imputed interest on related party loan  |  |  | 833 |  |  |  | 833 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | - | - | (4221) | (4221) |
| **Balance - October 31, 2022** | 39210000 | 3921 | 347338 |  |  | (402261) | (51002) |
| &nbsp;&nbsp;&nbsp;&nbsp;Imputed interest on related party loan  |  |  | 965 |  |  |  | 965 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock surrender, held as treasury stock  |  |  | 600 | (6000000) | (600) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - |  |  | (12396) | (12396) |
| **Balance - January 31, 2023** | 39210000 | $3921 | $348903 | (6000000) | $(600) | $(414657) | $(62433) |

---

***For the Three and Six Months Ended January 31, 2022***

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Additional**<br>**Paid in**<br> **Capital** |<br>**Accumulated**<br> **Deficit** |<br> **Total** |
| **Balance - July 31, 2021** | 39210000 | $3921 | $344963 | $(363996) | $(15112) |
| &nbsp;&nbsp;&nbsp;&nbsp;Imputed interest on related party loan |  |  | 67 |  | 67 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | (2507) | (2507) |
| **Balance - October 31, 2021** | 39210000 | 3921 | 345030 | (366503) | (17552) |
| &nbsp;&nbsp;&nbsp;&nbsp;Imputed interest on related party loan |  |  | 209 |  | 209 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss for the period | - | - | - | (6626) | (6626) |
| **Balance - January 31, 2022** | 39210000 | $3921 | $345239 | $(373129) | $(23969) |

---

*The accompanying notes to the unaudited financial statements are an integral part of these statements.*

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#TOC)* |

---

**PANAMERA HOLDINGS CORPORATION**

**Statements of Cash Flows**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the**  | **For the**  |
|  | **Six Months Ended** | **Six Months Ended** |
|  | **January 31,** | **January 31,** |
|  | **2023** | **2022** |
| **Cash Flows from Operating Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(16617) | $(9133) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Imputed interest on related party loan | 1798 | 276 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 5361 | 1633 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (1) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 55 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other receivable - related party | 1098 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue and customer deposits | (1500) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payroll liabilities - related party | 394 | - |
| Net Cash Used in Operating Activities | (9412) | (7224) |
| **Cash Flows from Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from related party loans | 10000 | 7228 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Cash Provided by Financing Activities | 10000 | 7228 |
| Net change in cash | 588 | 4 |
| Cash, beginning of period | 3087 | 10 |
| Cash, end of period | $3675 | $14 |
| Supplemental cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $- | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for taxes | $- | $- |
| Supplemental disclosure of non-cash financing activity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share surrender, heled as treasury stock | $600 | $- |

---

*The accompanying notes to the unaudited financial statements are an integral part of these statements.*

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#TOC)* |

---

**PANAMERA HOLDINGS CORPORATION**

**Notes to the Unaudited Interim Financial Statements**

**January 31, 2023**

**NOTE 1 – ORGANIZATION, DESCRIPTION OF BUSINESS**

Panamera Holdings Corporation (the "Company") is a Nevada corporation incorporated on May 20, 2014. Effective October 21, 2021, the Company changed its name from Panamera Healthcare Corporation to Panamera Holdings Corporation and increased the number of authorized common stock from 150,000,000 shares of common stock to 550,000,000 shares of common stock, par value $0.0001 per share. The Company's fiscal year end is July 31.

The Company intended to offer management and consulting services to healthcare organizations but have redirected our efforts now to pursuing business opportunities including but not limited to the environmental services industry, emerging innovative technologies and individual health choices led by innovation with integration. To date, the Company's activities have been limited to its formation and the raising of equity capital and consulting services related to an agreement effective on March 1, 2022 with First DP Ventures, LP dba First Primary Care of Houston, Texas.

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

***Basis of Presentation***

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company's Annual Report on Form 10-K, for the year ended July 31, 2022, as filed with the SEC on January 06, 2023.

***Use of Estimates***

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

***Commitments and Contingencies***

The Company follows ASC 450-20, "Loss Contingencies," to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#TOC)* |

---

***Revenue Recognition***

The Company recognizes revenue from its contracts with customers in accordance with *ASC 606 – Revenue from Contracts with Customers.* The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.

Revenue related to contracts with customers is evaluated utilizing the following steps:

(i) Identify the contract, or contracts, with a customer;

(ii) Identify the performance obligations in the contract;

(iii) Determine the transaction price;

(iv) Allocate the transaction price to the performance obligations in the contract;

(v) Recognize revenue when the Company satisfies a performance obligation.

When the Company enters into a contract, the Company analyses the services required in the contract in order to identify the required performance obligations which would indicate the Company has met and fulfilled its obligations. For the current contracts in place, the Company has identified performance obligations as one single event, the sign-off by both parties that production is completed, and the product (film) is ready for distribution. To appropriately identify the performance obligations, the Company considers all of the services required to be satisfied per the contract, whether explicitly stated or implicitly implied. The Company allocates the full transaction price to the single performance obligation being satisfied.

The Company has one annual consulting contract that requires a fixed monthly payment of $8,333. The company recognizes the monthly revenue at the beginning of the month and any cash payments received in advanced are recorded as deferred revenue until all obligations have been met as specified in the related customer contract.

As of January 31, 2023, and July 31, 2022, the Company recorded a customer deposit of $0 and $1,500 for an advance on revenue, respectively.

***Reclassification***

Certain accounts from prior periods have been reclassified to conform to the current period presentation.

**NOTE 3 - GOING CONCERN**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of January 31, 2023, the Company has a loss from operations, an accumulated deficit of $414,657 and has earned limited revenues of $50,001. The Company intends to fund operations through debt and/or equity financing arrangements and related party advances, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2023.

The ability of the Company to emerge from an early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings.

These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**NOTE 4 - RELATED PARTY TRANSACTIONS**

During the six months ended January 31, 2023, and 2022, the Company's shareholders financed of $10,000 and $7,228 for operation expenses. As of January 31, 2023, and July 31, 2022, the Company was obliged for an unsecured, non-interest-bearing demand loan with balance of $43,946 and $33,946, respectively. The Company recognized interest of $1,798 on advance by related party and recorded it as additional paid-in-capital.

As discussed in Note 5, related parties surrendered common stock to the Company.

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#TOC)* |

---

During the six months ended January 31, 2023, the Company recognized and paid $44,000 salary to a member of the board of directors for services rendered to the Company. As at January 31, 2023 and July 31, 2022, the Company recognized a prepaid wages of $0 and $1,098 for overpayment of salary, respectively.

The Company does not own or lease property or lease office space. The office space used by the Company was arranged by the founder, who is also a director of the Company, to use at no charge.

**NOTE 5 - STOCKHOLDERS' EQUITY**

***Preferred Stock***

The Company has authorized 50,000,000 shares of preferred stock with a par value of $0.0001 per share. No preferred stock was issued or outstanding as at January 31, 2023 and July 31, 2022.

***Common Stock***

The Company has authorized 550,000,000 shares of common stock with a par value of $0.0001 per share.

On December 6, 2022, the Company entered into a share surrender agreement with two shareholders, who are also directors of the Company, whereby they voluntarily surrendered 6,000,000 shares of common stock to the Company to be held as treasury stock. The shares of common stock were originally issued as founders shares on May 21, 2014, at par value and therefore upon surrender there was no gain or loss.

As of January 31, 2023, there were 39,210,000 shares of common stock issued and 3,321,000 shares of common stock outstanding.

As of July 31, 2022, there were 39,210,000 shares of common stock issued and outstanding.

***Treasury stock***

The Company records treasury stock at cost. Treasury stock is comprised of shares of common stock purchased by the Company at par value. As of January 31, 2023, the Company had 6,000,000 shares of treasury stock valued at $600.

**NOTE 6 – CONCENTRATION**

*Revenue*

During the year ended July 31, 2022, the Company entered into a consulting agreement in the field of Healthcare for a monthly fee of $8,333 with First DP Ventures, LP. The services were performed by a member of the Company's board of directors pursuant to an Employment Contract. As of January 31, 2023, all revenue of $50,001 and accounts receivable of $8,333 were diverted from one customer.

*Cost of revenue*

During the six months ended January 31, 2023, the cost of revenue of $48,864 was for the payroll expenses related to a member of the Company's board of directors, who performed the consulting agreement 's services.

**NOTE 7– COMMITMENTS AND CONTINGENCIES**

The Company had no other commitments or contingencies as of January 31, 2023.

From time to time the Company may become a party to litigation matters involving claims against the Company.

Management believes that it is adequately insured for its operations and there are no current matters that would have a material effect on the Company's financial position or results of operations.

**NOTE 8 – SUBSEQUENT EVENTS**

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#TOC)* |

---

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

**FORWARD-LOOKING STATEMENTS**

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited financial statements are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to "common shares" refer to the common shares in our capital stock.

As used in this quarterly report, the terms "we", "us", "our" and "our Company" mean Panamera Holdings Corporation, unless otherwise indicated.

**General Overview**

We were incorporated under the laws of the State of Nevada on May 20, 2014. Effective October 21, 2021, the Company changed its name from Panamera Healthcare Corporation to Panamera Holdings Corporation and increased the number of authorized common stock from 150,000,000 shares of common stock to 550,000,000 shares of common stock, par value $0.0001per share. Prior management intended to offer management and consulting services to healthcare organizations, but current management have redirected our efforts now to pursuing business opportunities including but not limited to the environmental services industry, emerging innovative technologies and individual health choices led by innovation with integration.

We have since changed our focus to looking for other business opportunities to implement and/or operating companies with which to engage in a business combination as described above. As we pursue those other business opportunities, we have commenced business operations by engaging to act as a consultant to a healthcare organization through the services of an employee pursuant to a consulting agreement with First DP Ventures, LP dba First Primary Care of Houston, Texas as referenced in the 8-K filed May 24, 2022.

Our address is 1218 Webster Street, Houston, Texas. Our telephone number is (713) 289-6200.

We have not ever declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include but are not limited to those discussed below and elsewhere in this report. Our unaudited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#TOC)* |

---

***COVID-19***

A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. The Company considered the impact of COVID-19 on the assumptions and estimates used and determined that there were no material adverse impacts on the Company's results of operations and financial position as of January 31, 2023. The full extent of the future impacts of COVID-19 on the Company's plan of operations is uncertain. A prolonged outbreak could have a material adverse impact on the Company's ability to identify and implement new business opportunities and/or consummate an acceptable merger or acquisition transaction.

**Plan of Operations and Cash Requirements**

We are no longer attempting to implement our original business plan. We now intend to look for other business opportunities to implement and/or operating companies with which to engage in a business combination including but not limited to the environmental services industry, emerging innovative technologies and individual health choices led by innovation with integration. Our focus will be on achieving long-term growth potential.

As we pursue those other business opportunities, we have commenced business operations by engaging to act as a consultant to a healthcare organization, First DP Ventures, LP dba First Primary Care of Houston, Texas, through the services of an employee.

The analysis of new business opportunities will be undertaken by or under the supervision of the Company's management. While the Company has limited assets and minimal operating revenues, the Company has unrestricted flexibility in seeking, analyzing and participating in potential business opportunities and/or combinations in in any type of business, industry or geographical location. In its efforts, the Company will consider the following kinds of factors:

(a) potential for growth, indicated by new technology, anticipated market expansion or new products.

(b) competitive position as compared to other operations of similar size and experience within the industry segment as well as within the industry as a whole.

(c) strength and diversity of management, either in place or scheduled for recruitment.

(d) capital requirements and anticipated availability of required funds, to be provided by the Company or from operations, through the sale of additional securities, through joint ventures or similar arrangements or from other sources.

(e) the cost of participation by the Company as compared to the perceived tangible and intangible values and potentials.

(f) the extent to which the business opportunity can be advanced; and

(g) the accessibility of required management expertise, personnel, raw materials, services, professional assistance and other required items.

In applying the foregoing criteria, not one of which will be controlling, management will attempt to analyze all factors and circumstances and make a determination based upon reasonable investigative measures and available data. Potentially available opportunities may occur in many different industries, and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex. Due to the Registrant's limited capital available for investigation, the Registrant may not discover or adequately evaluate adverse facts about the opportunity to be acquired. In addition, we will be competing against other entities that possess greater financial, technical and managerial capabilities for identifying and completing the implementation of any opportunities and/or business combinations.

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#TOC)* |

---

**Results of Operations**

The following summary of our results of operations should be read in conjunction with our unaudited financial statements for the period ended January 31, 2023, which are included herein.

Our operating results for the three months ended January 31, 2023 and 2022 and the changes between those periods for the respective items are summarized as follows.

*Results of Operations for the three months ended January 31, 2023 and 2022*

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | |
|  | **January 31,** | **January 31,** | |
|  | **2023** | **2022** | <br><br>**Changes**  |
| Revenues  | $25000 | $- | $25000 |
| Cost of revenues | $25970 | $- | $25970 |
| Operating expenses | $10461 | $6237 | $4224 |
| Interest expense | $965 | $389 | $576 |
| Net loss | $12396 | $6626 | $5770 |

---

During the three months ended January 31, 2023, and 2022, we generated $25,000 and $0 revenues, respectively. The revenues are related to consulting services rendered to one customer and $16,667 has been paid and January 2023 fees of $8,333 has been paid on February 1, 2023.

We had a net loss of $12,396 for the three months ended January 31, 2023, and $6,626 for the three months ended January 31, 2022. The increase in net loss of $5,770, was due to an increase in gross loss of $970, operating expenses of $4,224 and interest expenses of $576.

Cost of revenues for the three months ended January 31, 2023 and 2022, were $25,970 and $0, respectively. The cost of revenues was for the payroll expenses related to a member of the Company's board of directors, who performed the consulting agreement 's services.

Operating expenses for the three months ended January 31, 2023 and 2022 were $10,461and $6,237, respectively. For the three months ended January 31, 2023, the operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission ("SEC") of $8,167 and general and administrative expenses of $2,294. For the three months ended January 31, 2022, the operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission ("SEC") of $5,305 and general and administrative expenses of $932.

Interest expenses for the three months ended January 31, 2023, and 2022, represent interest expense of $965 and $389 to a related party on funds advanced to the Company, respectively.

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#TOC)* |

---

 *Results of Operations for the six months ended January 31, 2023 and 2022*

---

| | | | |
|:---|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** | |
|  | **January 31,** | **January 31,** | |
|  | **2023** | **2022** | <br><br>**Changes**  |
| Revenues  | $50001 | $- | $50001 |
| Cost of revenues | 48864 |  | $48864 |
| Operating expenses | 15956 | 8677 | $7279 |
| Interest expense | 1798 | 456 | $1342 |
| Net loss | $16617 | $9133 | $7484 |

---

During the six months ended January 31, 2023, and 2022, we generated $50,001 and $0 revenues, respectively. The revenues are related to consulting services rendered to one customer and $41,668 has been paid and January 2023 fees of $8,333 has been paid on February 1, 2023.

We had a net loss of $16,617 for the six months ended January 31, 2023, and $9,133 for the six months ended January 31, 2022. The increase in net loss of $7,484, was due to an increase in gross profit of $1,137, offset by an increase in operating expenses of $7,279 and interest expenses of $1,342.

Cost of revenues for the six months ended January 31, 2023 and 2022, were $48,864 and $0, respectively. The cost of revenues was for the payroll expenses related to a member of the Company's board of directors, who performed the consulting agreement 's services.

Operating expenses for the six months ended January 31, 2023 and 2022 were $15,956 and $8,677, respectively. For the six months ended January 31, 2023, the operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission ("SEC") of $13,219 and general and administrative expenses of $2,737. For the six months ended January 31, 2022, the operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission ("SEC") of $5,333 and general and administrative expenses of $3,344.

Interest expenses for the six months ended January 31, 2023, and 2022, represent interest expense of $1,798 and $456 to a related party on funds advanced to the Company, respectively.

**Balance Sheet Data:**

---

| | | | |
|:---|:---|:---|:---|
|  | **January 31,**<br>**2023** | **July 31,**<br>**2022** | **Changes**  |
| Cash | $3675 | $3087 | $588 |
| Working capital deficiency | $(62433) | $(47614) | $(14819) |
| Total assets | $12008 | $12572 | $(564) |
| Total liabilities | $74441 | $60186 | $14255 |
| Total stockholders' deficit | $(62433) | $(47614) | $(14819) |

---

As of January 31, 2023, our current assets were $12,008, and our current liabilities were $74,441 which resulted in working capital deficiency of $62,433. As of January 31, 2023, current assets were comprised of $3,675 in cash and $8,333 in accounts receivable, compared to $3,087 in cash, $55 in prepaid expenses, $8,332 in accounts receivable and $1,098 in other receivable-related party as of July 31, 2022. As of January 31, 2023, current liabilities were comprised of $22,395 in accounts payable, $43,946 in due to related party and $8,100 in payroll liabilities -related party, compared to $17,034 in accounts payable, $33,946 in due to related party, $7,706 in payroll liabilities -related party and $1,500 in customer deposit as of July 31, 2022.

As of January 31, 2023, our working capital deficiency increased by $14,819 from $47,614 on July 31, 2022, to $62,433 on January 31, 2023, primarily due to an increase in current liabilities of $14,255 and a decrease in current assets of $564.

---

| |
|:---|
| 13 |
| *[**Table of Contents**](#TOC)* |

---

**Cash Flow Data:**

---

| | | | |
|:---|:---|:---|:---|
|  | **Six Months Ended** | **Six Months Ended** | |
|  | **January 31,** | **January 31,** | |
|  | **2023** | **2022** | <br><br>**Changes**  |
| Cash Flows used in Operating Activities | $(9412) | $(7224) | $(2188) |
| Cash Flows used in Investing Activities | $- | $- | $- |
| Cash Flows provided by Financing Activities | $10000 | $7228 | $2772 |
| Net Change in Cash During Period | $588 | $4 | $584 |

---

***Cash Flows from Operating Activities***

We have not generated positive cash flows from operating activities. For the six months ended January 31, 2023, net cash flows used in operating activities was $9,412, consisting of a net loss of $16,617, reduced by imputed interest on related party loan of $1,798, reduced by an increase in accounts payable of $5,361 and by a decrease in prepaid expenses of $55, other receivable -related party of $1,098, payroll liabilities -related party of $394 offset by an increase in accounts receivable of $1and a decrease in customer deposit of $1,500.

For the six months ended January 31, 2022, net cash flows used in operating activities was $7,224, consisting of a net loss of $9,133, reduced by imputed interest on related party loan of $276 and reduced by an increase in accounts payable of $1,633.

***Cash Flows from Financing Activities***

We have financed our operations loans from a related party. For the six months ended January 31, 2023, and 2022, we received $10,000 and $7,228 from advances to pay certain operation expenses from related party loans, respectively.

**Going Concern**

As of January 31, 2023, our company had a net loss of $16,617 and has earned $50,001 revenues. Our company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2023. The ability of our company to emerge from the development stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of our business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings. These factors, among others, raise substantial doubt about our company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

**Critical Accounting Policies**

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management's application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

Revenue Recognition

The Company recognizes revenue from its contracts with customers in accordance with ASC 606 – Revenue from Contracts with Customers. The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.

---

| |
|:---|
| 14 |
| *[**Table of Contents**](#TOC)* |

---

Revenue related to contracts with customers is evaluated utilizing the following steps:

(i) Identify the contract, or contracts, with a customer;

(ii) Identify the performance obligations in the contract;

(iii) Determine the transaction price;

(iv) Allocate the transaction price to the performance obligations in the contract;

(v) Recognize revenue when the Company satisfies a performance obligation.

When the Company enters into a contract, the Company analyses the services required in the contract in order to identify the required performance obligations which would indicate the Company has met and fulfilled its obligations. For the current contracts in place, the Company has identified performance obligations as one single event, the sign-off by both parties that production is completed, and the product (film) is ready for distribution. To appropriately identify the performance obligations, the Company considers all of the services required to be satisfied per the contract, whether explicitly stated or implicitly implied. The Company allocates the full transaction price to the single performance obligation being satisfied.

The company recognizes the monthly revenue at the beginning of the month and any cash payments received in advanced are recorded as deferred revenue until all obligations have been met as specified in the related customer contract.

During the year ended July 31, 2022, the Company entered in a consulting agreement in the field of Healthcare for monthly $8,333 with First DP Ventures, LP. The services were performed by a member of the Company's board of directors pursuant to an Employment Contract. As of January 31, 2023, all revenue of $50,001 and accounts receivable of $8,333 were diverted from one customer.

Cost of revenue

During the six months ended January 31, 2023, the cost of revenue of $48,864 was for the payroll expenses related to a member of the Company's board of directors, who performed the consulting agreement 's services.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

As a "smaller reporting company," we are not required to provide the information required by this Item.

**Item 4. Controls and Procedures.**

***Evaluation of Disclosure Controls and Procedures***

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

---

| |
|:---|
| 15 |
| *[**Table of Contents**](#TOC)* |

---

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of January 31, 2023. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses: (1) lack of a functioning audit committee, (2) lack of a majority of outside directors on our Board of Directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (3) inadequate segregation of duties consistent with control objectives; and (4) management is dominated by two individuals without adequate compensating controls.

A "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements would not be prevented or detected on a timely basis.

We expect to be materially dependent upon a third party to provide us with accounting consulting services for the foreseeable future. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures and internal control over financial reporting will not result in errors in our financial statements which could lead to a restatement of those financial statements.

***Changes in Internal Controls***

There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the six months ended January 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

---

| |
|:---|
| 16 |
| *[**Table of Contents**](#TOC)* |

---

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings.**

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. We are not involved in any pending legal proceeding or litigation, and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party, and which would reasonably be likely to have a material adverse effect on our Company. To date, our Company has never been involved in litigation, as either a party or a witness, nor has our Company been involved in any legal proceedings commenced by any regulatory agency against our Company.

**Item 1A. Risk Factors.**

As a "smaller reporting company," we are not required to provide the information required by this Item.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

None.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not Applicable.

**Item 5. Other Information.**

On December 2, 2022, our transfer agent files were successfully transitioned from Action Stock Transfer's accounts to Securities Transfer Corporation ("STC"). STC is now our stock transfer agent with offices at 2901 N Dallas Parkway Suite 380, Plano, Texas 75093.

---

| |
|:---|
| 17 |
| *[**Table of Contents**](#TOC)* |

---

**Item 6. Exhibits.**

The following exhibits are included as part of this report:

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| **(3)** | **Articles of Incorporation and Bylaws** |
| [3.1](http://www.sec.gov/Archives/edgar/data/1620749/000155724014000539/ex_3-1.htm) | [Articles of Incorporation (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)](http://www.sec.gov/Archives/edgar/data/1620749/000155724014000539/ex_3-1.htm) |
| [3.2](http://www.sec.gov/Archives/edgar/data/1620749/000155724014000539/ex_3-2.htm) | [Bylaws (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)](http://www.sec.gov/Archives/edgar/data/1620749/000155724014000539/ex_3-2.htm) |
| **(14)** | **Code of Ethics** |
| [14.1](http://www.sec.gov/Archives/edgar/data/1620749/000155724014000539/ex_14-1.htm) | [Code of Ethics for Directors, Officers, and Employees (incorporated by reference to exhibit 14.1 in our Registration Statement on Form S-1 filed on September 26, 2014)](http://www.sec.gov/Archives/edgar/data/1620749/000155724014000539/ex_14-1.htm) |
| [14.2](http://www.sec.gov/Archives/edgar/data/1620749/000155724014000539/ex_14-2.htm) | [Code of Ethics for CEO And Senior Financial Officers (incorporated by reference to exhibit 14.2 in our Registration Statement on Form S-1 filed on September 26, 2014)](http://www.sec.gov/Archives/edgar/data/1620749/000155724014000539/ex_14-2.htm) |
| **(31)** | **Rule 13a-14 (d)/15d-14d) Certifications** |
| [31.1\*](pnht_ex311.htm) | [Section 302 Certification by the Principal Executive Officer](pnht_ex311.htm) |
| [31.2\*](pnht_ex311.htm) | [Section 302 Certification by the Principal Financial Officer and Principal Accounting Officer](pnht_ex311.htm) |
| **(32)** | **Section 1350 Certifications** |
| [32.1\*\*](pnht_ex321.htm) | [Section 906 Certification by the Principal Executive Officer](pnht_ex321.htm) |
| 101\* | Inline XBRL Document Set for the condensed financial statements and accompanying notes in Part I, Item 1, "Financial Statements" of this Quarterly Report on Form 10-Q. |
| 104\* | Inline XBRL for the cover page of this Quarterly Report on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set. |

---

*\** *Filed herewith.*

*\*\** *Furnished herewith.*

---

| |
|:---|
| 18 |
| *[**Table of Contents**](#TOC)* |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | **PANAMERA HOLDINGS CORPORATION** |
|  | (Registrant) |
| Dated: March 21, 2023 | */s/ T. Benjamin Jennings* |
|  | T. Benjamin Jennings |
|  | President, Chief Executive Officer and Director |
|  | (Principal Executive Officer) |

---

## Exhibit 31.1

**EXHIBIT 31.1 / 31.2**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND**

**PRINCIPAL ACCOUNTING AND FINANCIAL OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT AND RULE 13A-14(A)**

**OR 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934**

I, T. Benjamin Jennings, certify that:

1. I have reviewed this report on Form 10-Q of Panamera Holdings Corporation for the quarter ended January 31, 2023;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Dated: March 21, 2023 | By: | */s/ T. Benjamin Jennings* |
|  |  | T. Benjamin Jennings |
|  |  | President, Chief Executive Officer and Director |
|  |  | (Principal Executive Officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1 / 32.2**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND**

**PRINCIPAL ACCOUNTING AND FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Panamera Holdings Corporation (the "Company"), for the quarter ended January 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, T. Benjamin Jennings, President, Chief Executive Officer and Director (Principal Executive Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

---

| | | |
|:---|:---|:---|
| Dated: March 21, 2023 | By: | */s/ T. Benjamin Jennings* |
|  |  | T. Benjamin Jennings |
|  |  | President, Chief Executive Officer and Director |
|  |  | (Principal Executive Officer) |

---